/
DYAI
$0.88+$0.08 (+9.86%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$29.2M
36M shares
52-week range
$0.65 – $1.35
33% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.47%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2.75
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.7M | $1.6M | $2.4M | $2.9M | $2.9M | $3.5M | $1.2M |
| Cost of revenue | $1.0M | $1.5M | $1.4M | $1.9M | $2.1M | $2.0M | $1.2M | $2.3M |
| Gross profit | $268.2K | $221.4K | $177.0K | $459.4K | $807.1K | $923.0K | $2.3M | −$1.1M |
| Gross margin | 20.7% | 13.2% | 11.0% | 19.1% | 27.5% | 31.8% | 65.8% | -88.3% |
| R&D | $3.3M | $5.4M | $3.9M | $8.4M | $4.5M | $3.3M | $2.0M | $2.2M |
| Operating income | −$7.6M | −$9.3M | −$10.0M | −$14.7M | −$10.2M | −$8.2M | −$5.9M | −$7.1M |
| EBITDA | −$7.6M | $0 | −$10.0M | −$11.1M | −$10.1M | −$8.2M | −$5.4M | −$6.9M |
| Net income | −$5.7M | −$8.3M | −$9.3M | −$13.1M | −$9.7M | −$6.8M | −$5.8M | −$7.4M |
| Net margin | -439.4% | -494.2% | -582.1% | -543.7% | -332.2% | -234.4% | -166.2% | -597.6% |
| EPS (diluted) | -0.21 | -0.31 | -0.34 | -0.47 | -0.34 | -0.24 | -0.20 | -0.23 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $7M | $-0.10 | $-0.13–$-0.07 | 2 |
| 2027 | $13M | $0.04 | $0.03–$0.06 | 2 |
| 2028 | $11M | $-0.01 | $-0.01–$-0.01 | 1 |
| 2029 | $20M | $0.24 | $0.16–$0.31 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Dyadic International, Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
www.dyadic.com- Employees
- 5
- IPO / List date
- Nov 5, 2004
- HQ
- JUPITER, FL
Held by traders on TradeandTell
No one on the platform currently holds DYAI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 81,665 | $67.0K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded DYAI yet.
